A few disappointing earnings reports are dragging down a handful of the stocks that make up the 2022 Tax Loss Selling Recovery Portfolio.
Option premiums are solid, and liquidity is good, making this $5 stock an effective covered call candidate.
You might not immediately think of this name as a big winner over the last two years.
The fundamentals and the charts are on the same page.
The charts of this biotech name are setting up impressively right now.
The EV maker looks ripe for a dip, while the pharmaceutical giant and chip producer could make for swing trades.
The technical signals of the diversified health care company still don't inspire confidence to establish long positions in its stock at this time.
A closer look at the fund's composition leads to a few head-scratchers, but most of the names seem to fairly represent its focus.
As several parts of the world struggle with Covid-19 surges, MRNA could win in the long war against the pandemic.
The dividend in ABBV is key to making any investment decision regarding the stock.